Inogen, Inc. (INGN Quick QuoteINGN - Free Report) is well-poised for growth in the coming quarters, backed by high prospects in the portable oxygen concentrator (POC) space. The optimism, led by a diversified and expanding product portfolio, strong momentum in international markets and a growing total addressable market, seems justified. However, U.S. revenue pressure from channel shifts and macroeconomic conditions remains a key risk.

This Zacks Rank #3 (Hold) company’s shares have lost 4.6% in the year-to-date period compared with the industry’s 16.6% decline. However, the S&P 500 has risen 9.2% during the same timeframe.

The renowned provider of POCs has a market capitalization of $173.5 million. The company projects 16.3% earnings growth for 2026 and anticipates continued business improvements going forward. Inogen’s P/S ratio of 0.5 compared with the industry’s 2.7 makes its valuation attractive.

Image Source: Zacks Investment Research

Let’s delve deeper.

Factors Driving INGN’s Prospects

High Prospects in the POC Space & LTOT Market: Inogen is evolving from a pure-play portable oxygen concentrator manufacturer into a diversified home respiratory care platform spanning oxygen therapy, sleep therapy, airway clearance and digital health. This expands its estimated TAM beyond $3.4 billion. The company’s strategy leverages overlapping patient populations, HME channels and physician relationships to drive cross-selling. POCs remain core, with nearly 60% of new LTOT patients now starting therapy with a POC, up from under 40% a few years ago.

Focus on R&D and Clinical Evidence: Inogen is increasing investment in R&D, clinical studies and product innovation to strengthen differentiation and reimbursement support. First-quarter 2026 R&D spending rose due to funding for clinical and economic evidence generation. The company is advancing Simeox, targeting an estimated $500 million U.S. TAM in non-cystic fibrosis bronchiectasis. Patient enrollment has begun in the IMPACTS-200 reimbursement trial, aimed at building evidence for CMS and private payer reimbursement.

International Growth & Product Portfolio Expansion: International sales grew 18% year over year to $37.7 million in first-quarter 2026, driven by stronger commercial execution, deeper HME relationships and expansion into Eastern Europe, Latin America and Asia-Pacific. Inogen launched the Rove 6 Portable Oxygen Concentrator in Brazil, highlighting long-term opportunities in Latin America as home oxygen therapy adoption rises and global COPD markets remain underpenetrated.

The company launched the Aurora CPAP mask family in the United States and plans to present 90-day in-home evaluation results at SLEEP 2026. Management estimates the U.S. CPAP mask market at $2.2 billion. Early Aurora feedback, reorder trends and HME reception are encouraging, while Voxi 5 is showing favorable attachment rates and cross-selling momentum.

INGN: Key Risks to Watch

Macroeconomic & Supply Chain Exposure: Inogen remains exposed to macroeconomic pressures that may affect demand, supplier stability and component availability. Inflation, wage increases, logistics expenses and potential tariff changes could raise manufacturing and distribution costs. Although management does not currently expect proposed tariffs to materially impact results, ongoing cost volatility may pressure gross margins and slow profitability improvement, as the company increases upfront investment in new product categories and clinical commercialization efforts.

Mix Shift Weighs on U.S. Direct-to-Consumer and Rentals: The ongoing shift toward POCs as first-start therapy reduces the need for patients to switch from oxygen tanks through Inogen’s direct-to-consumer channel. In first-quarter 2026, U.S. sales declined 5% year over year to $34.7 million, while U.S. rental revenues fell 8% to $12.7 million. Management expects the rental business to remain pressured through 2026, potentially limiting scale efficiencies and profitability in the direct business despite continued growth in provider-channel volumes.

Dependence on Reimbursement for Rental Economics: Inogen’s direct-to-consumer rental model relies heavily on reimbursement from Medicare and other third-party payors, exposing the business to policy and reimbursement-rate risks. In first-quarter 2026, Medicare service reimbursement programs contributed 62.6% of rental revenues, reflecting high concentration. As the company expands products like Simeox, broader reimbursement coverage still depends on building clinical and economic evidence. Unfavorable reimbursement changes or limited coverage decisions could reduce rental profitability and slow adoption among channel partners.

INGN’s Estimate Trend

Inogen has been witnessing a stable estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for its loss per share has remained stable at 72 cents.

The Zacks Consensus Estimate for 2026 revenues is pegged at $369.3 million, suggesting a 5.9% improvement from the year-ago reported number.

Key Picks

Some top-ranked stocks from the broader medical space are West Pharmaceutical (WST Quick QuoteWST - Free Report) , Globus Medical (GMED Quick QuoteGMED - Free Report) and Intuitive Surgical (ISRG Quick QuoteISRG - Free Report) .

West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical’s shares have gained 14.9% against the industry’s 9.4% decline in the year-to-date period.

Globus Medical, currently sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Globus Medical’s shares have lost 3.1% compared with the industry’s 16.6% decline in the year-to-date period.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Intuitive Surgical’s shares have dropped 22.3% compared with the industry’s 16.6% decline in the year-to-date period.